David Singer

David Singer

Auto-generated profile, based on publicly available information

David Singer

GSK, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
RPRaunak Parikh
Raunak Parikh
DSDavid Singer
David Singer
ECElizabeth Chmielewski-Yee
Elizabeth Chmielewski-Yee
CDChristophe Dessart
Christophe Dessart
The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes zoster (HZ) in 2017. We conducted a literature search (January 1, 2017-August 1, 2023) using PubMed, Embase, and Scopus to consolidate the real-world evidence related to RZV. Overall, RZV effectiveness against HZ was high across the studied populations in real-world settings, including adults aged ≥ 50 years and patients aged ≥ 18 years with immunodeficiency or immunosuppression. Effectiveness was higher with two doses versus one dose, especially in elderly people and immunocompromised individuals. The safety profile of RZV was broadly consistent with that established in clinical trials. RZV does not appear to increase the risk of disease flares in patients with immune-mediated diseases. Approximately two-thirds of individuals received a second RZV dose within 2-6 months after the first dose. Collectively, RZV effectiveness against HZ was high, and these real-world studies reaffirm its favorable benefit-risk profile.

30 December 2022 in Gastroenterology Report
Verified
Journal Article
Open access
PDF file
DSDavid Singer
David Singer
PTPhilippe Thompson-Leduc
Philippe Thompson-Leduc
DGDeepshekhar Gupta
Deepshekhar Gupta
WCWendy Y Cheng
Wendy Y Cheng
SPSara Poston
Sara Poston
FFFrancis A Farraye
Francis A Farraye
Background: Patients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ). We evaluated the incidence of HZ in ulcerative colitis (UC) and Crohn’s disease (CD) patients and compared this with HZ incidence in a non-IBD population.Methods: We conducted a retrospective cohort study (GSK study identifier: VEO-000043) of adults aged ≥18 years with UC and CD and without IBD who were identified from claims recorded in a US healthcare database between October 2015 and February 2020. Crude HZ incidence rates/1,000 person-years (PY) were calculated, and comparisons of HZ incidence rates between UC or CD and non-IBD cohorts were made using adjusted generalized linear models.Results: The study population comprised a total of 29,928 UC, 25,959 CD, and 11,839,329 non-IBD patients. Crude overall HZ incidence rates were 13.64/1,000 PY (UC), 15.94/1,000 PY (CD), and 7.95/1,000 PY (non-IBD). UC and CD patients had increased HZ incidence rates, with adjusted incidence rate ratios of 1.35 (95% confidence interval [CI], 1.26–1.44) and 1.66 (95% CI, 1.56–1.77), respectively, compared with non-IBD patients. Stratified analysis indicated increased relative rates of HZ in progressively younger age strata in the UC and CD patients compared with non-IBD patients. HZ incidence rates were higher in UC and CD patients who had previously received thiopurines or methotrexate, TNF-inhibitors, or corticosteroids than in UC and CD patients who did not take those medicines.Conclusion: UC and CD patients had increased HZ incidence rates compared with patients without IBD, demonstrating the importance of HZ prevention in IBD patients.

1 February 2023 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
DSDavid Singer
David Singer
PTPhilippe Thompson-Leduc
Philippe Thompson-Leduc
SPSara Poston
Sara Poston
DGDeepshekhar Gupta
Deepshekhar Gupta
WCWendy Y. Cheng
Wendy Y. Cheng
JCJeffrey R. Curtis
Jeffrey R. Curtis
Objective: To estimate the incidence of herpes zoster (HZ) in patients with rheumatoid arthritis (RA) compared with the general population in the USA.Methods: This retrospective, longitudinal cohort study used data from an administrative claims database containing both commercial and Medicare Advantage Part D data, with a data period from October 2015 to February 2020. Patients were aged ≥ 18 years and divided into 2 cohorts: patients with RA and patients without RA. Diagnosis and procedure codes were used to identify HZ cases and calculate incidence rates (IRs) of HZ in the 2 cohorts. Data were stratified by age group (ie, 18-49, 18-29, 30-39, 40-49, 50-64, and ≥ 65 yrs) and RA therapy type. IR ratios (IRRs), adjusted by cohort baseline characteristics, were estimated using generalized linear models to compare the incidence of HZ between cohorts.Results: The overall IR of HZ was higher in the RA cohort (21.5 per 1000 person-years [PY]; N = 67,650) than in the non-RA cohort (7.6 per 1000 PY; N = 11,401,743). The highest IRs in both cohorts were observed in the age group of ≥ 65 yrs (23.4 and 11.4 per 1000 PY in the RA cohort and non-RA cohort, respectively). The overall adjusted IRR of HZ was 1.93 (95% CI 1.87-1.99,P< 0.001) for the RA cohort compared with the non-RA cohort. In the RA cohort, the highest IRs by medication class were observed in patients using corticosteroids and those using Janus kinase inhibitors.Conclusion: These results highlight the increased incidence of HZ in patients with RA.

9 December 2024 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
ELElizabeth M. La
Elizabeth M. La
JGJonathan Graham
Jonathan Graham
DSDavid Singer
David Singer
DMDaniel Molnar
Daniel Molnar
SPSara Poston
Sara Poston
FVFrederik Verelst
Frederik Verelst
Respiratory syncytial virus (RSV) is a common cause of acute respiratory illness in individuals of all ages, with adults aged ≥60 years and adults with certain chronic conditions at increased risk of severe RSV-related outcomes. This study evaluates the cost-effectiveness of the adjuvanted RSVPreF3 vaccine versus no vaccine in adults aged ≥60 years in the United States (US). A multi-cohort Markov model was developed with a 5-year time horizon and 1-month cycle length to compare outcomes for no vaccination and one-time adjuvanted RSVPreF3 vaccination (assuming the same vaccination as for influenza vaccines). Clinical parameters (e.g., vaccine efficacy) were based on phase 3 clinical trial data over 3 seasons, with all other inputs obtained from public US sources and scientific literature. Outcomes included total and incremental quality-adjusted life year (QALY) losses and costs, as well as incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were conducted to evaluate the sensitivity of results to inputs. In the base case, the model estimated that vaccinating 52.7 million adults aged ≥60 years with the adjuvanted RSVPreF3 vaccine once would result in 244,424 fewer QALY losses and an incremental societal cost of $4.5 billion over 5 years, with vaccination costs partially offset by reduced disease-related costs. From the societal perspective, adjuvanted RSVPreF3 vaccination resulted in an ICER of $18,430 per QALY gained. Results were relatively robust across sensitivity analyses and indicate that adjuvanted RSVPreF3 vaccination is a cost-effective option for the prevention of RSV in US adults aged ≥ 60 years, reducing the substantial burden within this population.

23 May 2023 in Rheumatology and Therapy
Verified
Journal Article
Open access
PDF file
DSDavid Singer
David Singer
PTPhilippe Thompson-Leduc
Philippe Thompson-Leduc
SPSara Poston
Sara Poston
DGDeepshekhar Gupta
Deepshekhar Gupta
WCWendy Y. Cheng
Wendy Y. Cheng
JCJeffrey R. Curtis
Jeffrey R. Curtis
Objective To estimate the incremental healthcare resource utilization (HRU) and cost burden posed by herpes zoster (HZ) in adult patients with rheumatoid arthritis (RA) in the United States. Methods A retrospective cohort study was conducted using an administrative claims database containing commercial and Medicare Advantage with Part D data, between October 2015 and February 2020. Patients with RA and HZ (RA+/HZ+) or RA without HZ (RA+/HZ−) were identified based on diagnosis codes and relevant medications. Outcomes measured included HRU and medical, pharmacy, and total costs at month 1, quarter 1, and year 1 after the index date (HZ diagnosis for RA+/HZ+ cohort, randomly assigned for RA+/HZ− cohort). Generalized linear models incorporating propensity scores and other covariates were used to estimate differences in outcomes between cohorts. Results A total of 1866 patients from the RA+/HZ+ cohort and 38,846 patients from the RA+/HZ− cohort were included. Hospitalizations and emergency department visits occurred more frequently in the RA+/HZ+ than the RA+/HZ− cohort, especially in the month after HZ diagnosis (adjusted incidence rate ratio [95% confidence interval (CI)] for hospitalizations: 3.4 [2.8; 4.2]; emergency department visits: 3.7 [3.0; 4.4]). Total costs were also higher in the month after HZ diagnosis (mean adjusted cost difference [95% CI]: $3404 [$2089; $4779]), with cost differences driven by increased medical costs ($2677 [$1692; $3670]). Conclusions These findings highlight the high economic burden of HZ among individuals with RA in the United States. Strategies to reduce the risk of HZ in patients with RA (such as vaccination) may serve to reduce this burden. Video abstract

23 December 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
DSDavid Singer
David Singer
YWYan Wang
Yan Wang
ELElizabeth M La
Elizabeth M La
SGSusan I Gerber
Susan I Gerber
AWAozhou Wu
Aozhou Wu
KBKeith A Betts
Keith A Betts
Background: Acute respiratory illnesses (ARIs) can be severe in older adults and adults with chronic conditions. We compared long-term outcomes of United States patients aged ≥50 years with ≥1 hospitalized ARI due to respiratory syncytial virus (RSV-ARI cohort) versus controls without ARI (control cohort) and patients with ≥1 hospitalized influenza-ARI (influenza-ARI cohort). Methods: This retrospective study used 1 October 2015–30 June 2023 claims data to evaluate clinical outcomes across the three cohorts. The index date was defined as the start of an ARI episode. Cumulative incidence functions assessed risks of readmission, all-cause mortality, myocardial infarction (MI), asthma and chronic obstructive pulmonary disease (COPD) exacerbation, and hospitalization due to heart failure (HHF); adjusted risks were compared using multivariable regression models. Results: A total of 14 759, 77 468, and 73 795 patients were selected into the RSV-ARI, influenza-ARI, and control cohorts, respectively. The RSV-ARI cohort had a substantially higher adjusted risk of all-cause mortality than controls, with the highest adjusted hazard ratio (95% confidence interval) 0–30 days post-index (10.772 [9.190, 12.627]). MI risk followed a pattern similar to all-cause mortality. Adjusted risks of asthma exacerbation, COPD exacerbation, and HHF were significantly higher in the RSV-ARI cohort than controls, and similar between RSV-ARI and influenza-ARI cohorts. Conclusions: RSV-ARI had considerable long-term impact on clinical outcomes, with measurable increases in outcomes associated with RSV-ARI when compared with controls, and similar outcomes compared to influenza-ARI. These findings can inform RSV prevention efforts and support future research on the long-term impact of RSV.